Provided by Tiger Trade Technology Pte. Ltd.

Goldman Sachs Future Health Care Equity ETF

36.49
-0.0328-0.09%
Post-market: 36.490.00000.00%16:10 EDT
Volume:129
Turnover:5K
Market Cap:19.16M
PE:- -
High:36.49
Open:36.49
Low:36.49
Close:36.52
52wk High:38.66
52wk Low:31.32
Shares:525.00K
Float Shares:525.00K
Volume Ratio:0.18
T/O Rate:0.02%
Dividend:0.11
Dividend Rate:0.31%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years

GlobeNewswire
·
Sep 30

Eli Lilly reports results from TRIUMPH-2 Phase 3 trial

TIPRANKS
·
Sep 30

Lilly's Experimental Drug Cuts Weight by 21% in Diabetes Trial

Reuters
·
Sep 30

Eli Lilly - Retatrutide 12 Mg Results in 49.6 Lb (20.8%) Weight Loss over 80 Weeks

THOMSON REUTERS
·
Sep 30

Lilly's Triple Agonist, Retatrutide, Delivered Substantial Weight Loss and A1c Reduction, Underscoring Its Potential Promise for People with Obesity and Type 2 Diabetes

THOMSON REUTERS
·
Sep 30

Eli Lilly - to Submit Biologics License Application for Retatrutide in Q1 2027

THOMSON REUTERS
·
Sep 30

Eli Lilly - 59.5% of Retatrutide 12 Mg Participants no Longer Meet Bmi Criteria for Obesity

THOMSON REUTERS
·
Sep 30

Liver safety concerns emerge for Bristol Myers’ admilparant, says Wells Fargo

TIPRANKS
·
Sep 30

Johnson: AI Providers Committed to Building Trust

THOMSON REUTERS
·
Sep 30

Johnson: We Can Keep Edge in a Safe Way

THOMSON REUTERS
·
Sep 30

Johnson: We'LL Continue to Assess and Deliberate in Coming Days

THOMSON REUTERS
·
Sep 30

US Drug Lobby Group PhRMA Names Former House Leader Cantor as CEO

Reuters
·
Sep 30

Cboe data shows mixed options sentiment in UnitedHealth with shares down 1.58%

TIPRANKS
·
Sep 30

Cigna: Announces Exclusive Agreement with UnitedHealth Global to Endorse Ghb as Preferred International Health Insurer - Website

THOMSON REUTERS
·
Sep 29

Cigna Global Health Benefits Signs Exclusive Endorsement Deal with UnitedHealthcare Global

Reuters
·
Sep 29

J&J : Bofa Global Research Raises Price Objective to $278 from $263

THOMSON REUTERS
·
Sep 29

J&J Says Imaavy Shows Sustained Disease Control Through Two Years in Adolescent Myasthenia Gravis Study

Reuters
·
Sep 29

J&J - no New Safety Signals Identified Through Two Years of Imaavy Treatment

THOMSON REUTERS
·
Sep 29

J&J - Presents New Data on Imaavy in Generalized Myasthenia Gravis

THOMSON REUTERS
·
Sep 29

J&J - Two-Year Phase 2/3 Data Shows Sustained Disease Control and Reduced Corticosteroid Use in Adolescents

THOMSON REUTERS
·
Sep 29